secwatch.observer — SEC 8-K summary
======================================

Issuer:     BioXcel Therapeutics, Inc. (BTAI)
CIK:        0001720893
Form:       8-K
Filed at:   2026-08-11T11:00:24+00:00
Accession:  0001104659-26-093710
Event type: debt
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioXcel extends debt repayment deadline to Aug 21, 2026; liquidity covenant cut to $3M
--------------------------------------------------------------------------------

- Twelfth Amendment to Credit Agreement with Oaktree dated Aug 10, 2026 extends acceptable transaction deadline from Aug 10 to Aug 21, 2026.
- Minimum liquidity covenant reduced to $3.0M from $6.25M effective Aug 10, 2026.
- Deadline requires definitive agreements for full repayment or alternative capital solution acceptable to Majority Lenders.
- Security Agreement amended to add three commercial tort claims as collateral (Cognitive Research, Caitlin Meyer, Segal Institute).
- All other Credit Agreement terms remain in full force; amendment does not waive lender rights.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1720893/000110465926093710/0001104659-26-093710-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1720893/000110465926093710/tm2622818d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-093710

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer